References
- Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, . B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006;65:859–64.
- Voswinkel J, Muller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener’s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005;1051:12–19.
- Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, . Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012;119:3691–7.
- Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, . Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus: a prospective pilot study. Rheumatology (Oxford) 2011;50:1640–4.
- Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, . Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77:542–8.
- Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, . EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605–17.
- Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
- Specks U, Ikle D, Stone JH. Induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:1865–6.
- Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla E, . Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013;42:1317–30.
- Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394–400.
- Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, . Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012;64:3760–9.
- Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006;45:724–9.
- Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, . Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180–8.
- Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, . Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement – a prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010;5:445–53.